Cookies on the NHS England website
Thousands of cancer patients in England are set to gain fast-tracked access to trials of personalised cancer vaccines following the launch of a world-leading NHS trial “matchmaking” service to help find new life-saving treatments.
The NHS today announced it has treated its first patient in England with a personalised vaccine against their bowel cancer, in a clinical trial part of NHS England’s new Cancer Vaccine Launch Pad.
In a national first, father-of-four Elliot Pfebve received the developmental jab at University Hospitals Birmingham NHS Foundation Trust, one of several sites taking part in the colorectal cancer vaccine trial sponsored by BioNTech SE.
The German biotechnology company will tomorrow (1 June) present new preliminary data at the American Society of Clinical Oncology’s annual conference in Chicago on how measuring circulating tumour DNA could potentially help early detection of colorectal cancer.
The vaccine trial involving Elliot is one of several that will be taking place in NHS trusts across the country to treat different types of cancer. Thousands more patients are expected to benefit from NHS England’s new Cancer Vaccine Launch Pad, which will enable those wanting to participate in clinical trials to be fast-tracked to one of the nearest participating hospitals.
_social_media.jpg)
